Results 211 to 220 of about 1,830,846 (361)

Are We Still Mediterranean? Dietary Quality and Adherence in Sicilian Women Undergoing ART: A Prospective Observational Cohort Study. [PDF]

open access: yesMedicina (Kaunas)
Liprino A   +6 more
europepmc   +1 more source

Medicina syringe breakage [PDF]

open access: yesAnaesthesia, 2015
C, Woo, D, de Beer, P, Evans
openaire   +2 more sources

Causal relationship between immune cells and idiopathic thrombocytopenic purpura: A bidirectional Mendelian randomization study

open access: yes
Rheumatology &Autoimmunity, EarlyView.
Heyi Zhang   +9 more
wiley   +1 more source

Personalized Cancer Vaccines in the Clinical Trial Pipeline

open access: yesAsia-Pacific Journal of Clinical Oncology, EarlyView.
This study analyzes the current landscape of personalized cancer vaccine clinical trials, highlighting trends in vaccine platforms, trial phases, and geographic distribution. Peptide and dendritic cell vaccines dominate early‐stage research, with promising immune responses observed in melanoma, glioblastoma, and urothelial cancer trials.
Liudmila Iamukova, Elena Alferova
wiley   +1 more source

ISUOG Consensus Statement on sonographic assessment of the endometrium: how to perform a gynecological ultrasound scan and report the findings

open access: yes
Ultrasound in Obstetrics &Gynecology, EarlyView.
T.  Van den Bosch   +20 more
wiley   +1 more source

The Prevalence of Symptomatic Dermographism: Results of the International UCARE PREVALENCE‐D Study

open access: yesAllergy, EarlyView.
An online expert‐designed questionnaire estimated the international prevalence of dermographism. Symptomatic dermographism, physiological red dermographism, and simple urticarial dermographism exhibit distinct prevalence patterns across age groups, sex, and geographic regions. Symptomatic dermographism has an international point prevalence of 3.20% (95%
Kanokvalai Kulthanan   +55 more
wiley   +1 more source

Medicina

open access: yes, 2012
Apunts mecanoscrits sobre història de la ...
openaire   +1 more source

Home - About - Disclaimer - Privacy